Please ensure Javascript is enabled for purposes of website accessibility

Mylan N.V. Reports Solid Q1 Revenue Growth, With Europe Leading the Way

By Keith Speights - May 3, 2016 at 2:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The generic drugmaker boosted revenue in the first quarter thanks largely to higher sales in Europe. But its outlook for the year most likely rests on how its bid to acquire a Swedish drugmaker plays out.


This has been a dismal year so far for Mylan N.V. (MYL) shareholders. The large generic drugmaker's stock was down nearly 23% year to date as of the beginning of May. But it released its first-quarter earnings results before the market opened on Tuesday. Were those results enough to turn things around? Here are the highlights.

Mylan results: The raw numbers


Q1 2016 Actuals

Q1 2015 Actuals

Growth (YOY)


$2.19 billion

$1.87 billion


Net income from continuing operations

$13.9 million

$56.6 million


Earnings per diluted share




YOY: Year over year. Data source: Yahoo! Finance. 

What happened with Mylan this quarter?
The good news for Mylan in the first quarter came from the nice revenue growth. On a constant currency basis, the numbers would have looked even better. Here's what drove the revenue growth:

  • Generic drug sales in Europe soared 45% year over year to $587.7 million. Although government-imposed pricing reductions and competition held prices down, Mylan more than made up for those headwinds through increased existing product sales, especially in France, plus new product sales.
  • North American generic drug sales (which now includes Brazilian sales) increased 8% year over year to $919.7 million. Higher new product sales outweighed sluggish existing product sales in the region.
  • Generic drug sales in the rest of the world grew 10% year over year to $420.8 million. Factors behind the increase included higher established drug sales and sales by Jai Pharma Ltd.
  • Specialty third-party net sales climbed 17% compared to the prior-year period to $247.9 million. Two products drove this growth: Mylan's EpiPen Auto-Injector and the Perforomist Inhalation Solution.

On the other hand, Mylan's bad news showed up on the bottom line. Earnings fell from the same period in 2015, primarily because of significantly higher operating expenses. However, on an adjusted basis, Mylan's earnings improved to $0.76 per diluted share -- a 9% jump from the prior-year period.

What management had to say
CEO Heather Bresch looked at the company's results with a positive outlook. She said:

We are off to a great start in 2016 with our strong first quarter results delivering year-over-year constant currency total revenues growth of 19% and adjusted diluted EPS growth of 9%. We showed again the strength and resilience of Mylan's diverse, global platform, with double digit revenue growth in Europe, Rest of World, and Specialty and high single digit revenue growth in North America.

Looking forward
Mylan reaffirmed its full-year 2016 revenue guidance range of $10.5 billion to $11.5 billion. The midpoint of that range reflects a 16% increase compared to 2015. The company also reaffirmed its 2016 adjusted earnings guidance range of $4.85 to $5.15 per share. At the midpoint, that also represents a 16% increase over 2015. 

Last year proved to be challenging for Mylan on the acquisitions front. Its shares took a beating after Teva Pharmaceuticals threw in the towel on buying the company. Teva tried hard to acquire Mylan, but continued rejections ultimately led the Israel-based generic drugmaker to pursue another opportunity.

Mylan's own attempt to buy Perrigo in a hostile takeover also met with failure, thanks to resistance from Perrigo's management and shareholders. The collapse of the buyout attempt actually helped Mylan's shares, though. Many observers viewed the potential acquisition as a bad move for Mylan.

Now, however, Mylan has its eyes set on Swedish drugmaker Meda. Mylan has tried a couple of times in the past to buy Meda, but with its new $9.9 billion offer, the third time might prove to be the charm. 

However, as with the doomed Perrigo deal, some believe that Mylan is making a mistake in offering to  buy Meda at such a high price. Mylan CEO Heather Bresch, though, said that the Meda acquisition "will further strengthen and diversify our business in terms of product portfolio, customer channels, and geography, and position us for continued growth and value creation over the near- and long-term." One way or the other, Mylan's stock performance in 2016 will likely be tied closely to what happens with this acquisition.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Viatris Inc. Stock Quote
Viatris Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.